Русский / English
Enter the query
Petrovax Pharm
the company makes significant investments in a broad range of research and development efforts

NPO Petrovax Pharm today

Research and Production Association (NPO) Petrovax Pharm is among the TOP5 immunobiological manufacturers in Russia and the TOP20 Russian pharmaceutical companies in terms of exports. Over the past 5 years, the facility’s revenues grew at a rate of 25% year on year, on average. The company’s sales territory embraces 12 foreign countries.

The company implements its R&D products into batch production at a state-of-the-art hi-tech biopharmaceutical facility. NPO Petrovax Pharm’s manufacture is fully compliant with the applicable Russian and international GMP and ISO:9001 standards.

Petrovax Pharm’s product portfolio includes branded pharmaceuticals and vaccines that originate both from the company’s own R&D efforts and cooperation with the lead local and foreign players. The company holds more than 20 patents to new molecules and manufacturing technologies. Its key focus areas are the development and production of influenza vaccines, immunobiologicals, pneumococcal vaccine, and innovative thrombolytics.

Petrovax Pharm has more than 600 skilled employees. It operates an R&D Center, Strategic Development Department, API and Finished Dosage Forms Production units, Quality Unit, Marketing and Promotion units, and Sales Department.

The company is a member of the Union of Professional Pharmaceutical Organizations (SPFO), Association of Russian Pharmaceutical Manufacturers (ARFP), Pharmaceutical and Medical Devices Industry Investor Club, nonprofit partnership “National Association of Infection Control Experts” and other industry-specific communities.

In 2017, Petrovax Pharm won All-Russia Contest “Russian Business Leaders: Performance and Commitment”. In 2018, the company was the winner of the National Import Substitution Award “PRIORITY-2018” for Grippol® Quadrivalent vaccine. In 2019, Petrovax Pharm’s top management team won the Russian Business Guide’s Award “People of the Year” for successful entrepreneurship and contribution to Russia’s economic development. Polyoxidonium® and Longidaze® are many-time winners of prestigious Russian Pharma Awards.

Petrovax Pharm’s key objective is production of innovative pharmaceuticals and vaccines resulting from fundamental research.

Petrovax Pharm’s products are in demand in many currently central healthcare areas, such as infectious diseases, preventive vaccination, immunology and pediatrics, urology, gynecology and reproductive health, cardiovascular diseases.

The company’s product portfolio formed in line with critical healthcare needs includes:
• Polyoxidonium® (azoximer bromide), a branded combined product with immunomodulating, detoxifying, and antioxidative action;
• Longidaze® (bovhyarulonidase azoximer), a sustained release enzyme for combined therapy of connective tissue hyperplasia diseases;
• Grippol® plus and Grippol® Quadrivalent, influenza vaccines;
• Prevenar® 13, a pneumococcal conjugate vaccine, 13-valent;
• Actilyse® (alteplase) and Metalyse® (tenecteplase), innovative thrombolytics for cardiovascular diseases;
• Velson® (melatonin), a state-of-the-art medication for sleep normalization and arranging human biorhythms;
• Imoferaza®, a skin care cream to specifically address scarred and adhesion sites.

The company keeps moving beyond by investing into R&D projects to create new products. In 2018, the first in Russia 4-valent influenza vaccine Grippol® Quadrivalent was launched to the market. Currently, a conjugate platform-based antiviral agent is in the company’s development pipeline.
NPO Petrovax Pharm is one of the most advanced and hi-tech pharmaceutical facilities in Russia manufacturing active substances and finished pharmaceutical products in a variety of dosage forms in full compliance with the applicable Russian and international GMP and ISO:9001 standards. The production capacity provides for manufacturing more than 160 million doses of immunobiological products per annum.

NPO Petrovax Pharm’s production and warehousing complex located in Podolsk of Moscow region was launched into operation in 2008. It was designed and constructed by Serbian OPART to EU GMP requirements. The operations started with launching a prefilled syringe line and Grippol® plus vaccine production. In 2009, the production line for Polyoxidonium® and Longidaze® ampoules and vials was launched. In 2019, the company was issued an approval for launching into operation of the 2nd manufacturing unit incorporating production lines for API, solid, soft, and liquid dosage forms. The investment into the capacity extension project exceeded 1 billion RUB, of which 300 million RUB were provided by the Industry Development Fund as an easy loan. When implemented, this project will provide for increasing production of APIs (2.5x), tablets (7x), and suppositories (4x) in 2020.

Importantly, NPO Petrovax Pharm is the first in Russia immunobiological manufacturer to be issued international GMP certificates (by the EU and Iran).

The conformance of NPO Petrovax Pharm’s Quality Assurance System (QAS) was many times confirmed by the audits performed by the world pharma leaders, including Pfizer, Abbott, Boehringer Ingelheim etc. Overall, since founded, Petrovax Pharm has successfully passed more than 50 Russian and foreign inspection visits, with positive findings on the QAS conformance to international GMP requirements.
NPO Petrovax Pharm has more than 600 skilled employees capable of meeting any hi-tech challenges.

The company has created favorable conditions for professional and career development. Specifically, a comprehensive training system for different employee categories is in place. The manufacturing staff are trained to GMP standards on a regular basis. Besides, the company funds external training of employees at advanced training centers. Certain specialists go abroad for international internship.
R&D and production excellence, innovation-centered approach, and professional expertise have shaped Petrovax Pharm into an attractive partner for the leading international pharma companies. Currently, Petrovax Pharm pursues successful cooperation projects with Abbott, Pfizer, and Boehringer Ingelheim.

In 2008, in partnership with Abbott (former Solvay Pharma), a construction project for a state-of-the-art pharmaceutical complex for the development and manufacturing of immunobiologicals to international GMP standards was successfully completed.

In 2015, in partnership with Pfizer, a full-cycle production localization project for Prevenar® 13, a 13-valent pneumococcal vaccine, was implemented. Since 2014, the vaccine has been supplied for the Russian National Immunization Schedule on an annual basis. This project received a Russian Platinum Ounce award in the Project of the Year subcategory.

In 2016, collaboration with Boehringer Ingelheim started for localization of Metalyse® and Actilyse® thrombolytics. The first commercial batches have already been supplied for the Russian market. The year 2019 is the scheduled date for the completion of a full-cycle production technology transfer for Actilyse®.

Due to international partnerships, NPO Petrovax Pharm has acquired unique expertise and production competence, enhanced the level of professional excellence for further brisk growth.
One of the outcomes of Petrovax Pharm’s participation in joint projects with the world pharma leaders is a growth of its export potential. This is of prime importance for the company as geographic expansion has always been its strategic objective.

While working towards reaching this objective, the company has yielded impressive results: presently, NPO Petrovax Pharm exports to 10 ex-Soviet countries such as Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Turkmenistan, Ukraine, and Uzbekistan, as well as to the EU (Slovakia) and Middle East regions (Iran). As of 2018, exports tolaling 1 billion RUB accounted for 12 % in Petrovax Pharm’s total sales.

NPO Petrovax Pharm supplies Grippol® plus vaccine to six countries, such as Belarus, Kazakhstan, Kyrgyzstan, Turkmenistan, Uzbekistan, and Iran, for their national population immunization programs.

The company continuously expands the range of post-authorization and epidemiology studies of its branded products to keep abreast of the current international requirements and have access to foreign markets.

Petrovax Pharm plans to expand its footprint on the existing markets as well as enter the markets of other EU countries besides Slovakia as well as those of South America, Southeast Asia, and Northern Africa.

Press Center
A Russian original medication called Polyoxidonium® by Petrovax, a pharmaceutical company affiliated to the Interros Group, has passed the first phase of an international clinical trial for its effectiveness and safety for COVID-19 treatment.
Polyoxidonium (azoximer bromide) - the Russian original drug produced by Petrovax-  was approved by the Ministry of Health of the Russian Federation for conducting an international clinical trial for the treatment of COVID-19.
The first place in the nomination «Medicine of choice for the treatment and prevention of SARS and influenza among children» was granted to «Polyoxidonium», produced by NGO Petrovax Pharm.
At a conference on communication in the pharmaceutical industry, delegates discussed issues relevant to the pharmaceutical industry and emphasized the importance of open conversation and ongoing dialogue between the media and market experts.
NPO Petrovax Pharm passed an audit by the State Institute of Pharmaceuticals Quality Control of Slovakia, and was once again awarded the EU GMP production and quality management compliance certificate.
Interros Group is acquiring a controlling stake in NPO Petrovax Pharm, a Russian pharmaceutical company.  The parties signed the documents in Moscow today. Arkady Nekrasov and Natalia Puchkova, NPO Petrovax Pharm founders, will retain a stake in the company, and will continue to participate in business management. Financial terms of the deal are not disclosed.